← Eichor
Condition: Hcc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hcc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Phase N/A · 1 location(s) · University of Missouri-Columbia · NCT02838836Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)
Phase N/A · 1 location(s) · National Cancer Institute, Naples · NCT06905262Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Qilu Hospital of Shandong University · NCT06571396Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepato
Phase 2 · 4 location(s) · Riboscience, LLC. · NCT07175441HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese
Phase N/A · 1 location(s) · Ruijin Hospital · NCT05870969Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06389422Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Phase 4 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT07059494A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves T
Phase 1 · 11 location(s) · AbbVie · NCT06487559Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06446154Evaluation of Risk of hEpatocellular Carcinoma
NA · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT06523179Improving Hepatocellular Carcinoma Screening
NA · 1 location(s) · Naik Vietti Violi · NCT05828446Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment
NA · 1 location(s) · Shanghai Zhongshan Hospital · NCT06794073EGCG for Hepatocellular Carcinoma Chemoprevention
Phase 2 · 1 location(s) · University of Texas Southwestern Medical Center · NCT06015022Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Phase 3 · 11 location(s) · Polaris Group · NCT05317819Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasib
Phase 1 · 1 location(s) · University Hospital, Lille · NCT04587739DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plu
Phase 1/Phase 2 · 1 location(s) · Yinghua Xu · NCT07495215Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With
Phase 3 · 3 location(s) · Beijing Shenogen Biomedical Co., Ltd · NCT05594927Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
Phase N/A · 1 location(s) · Zhongda Hospital · NCT06607120Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06766643The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation
NA · 1 location(s) · Iuliu Hatieganu University of Medicine and Pharmacy · NCT07657897Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT05444478HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06641713The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy
EARLY_Phase 1 · 1 location(s) · Sir Run Run Shaw Hospital · NCT05035108A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT07482059Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07099274AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Beijing Tsinghua Chang Gung Hospital · NCT07538882Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
NA · 1 location(s) · Tanta University · NCT06961526
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.